Cesca Therapeutics Inc (NASDAQ:KOOL) has earned an average broker rating score of 0.00 () from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating.
Zacks has also assigned Cesca Therapeutics an industry rank of 104 out of 265 based on the ratings given to related companies.
Separately, Maxim Group restated a “hold” rating on shares of Cesca Therapeutics in a research report on Monday, December 5th.
In other Cesca Therapeutics news, major shareholder (Hong Kong) Ltd Boyalife bought 6,102,942 shares of Cesca Therapeutics stock in a transaction that occurred on Monday, December 26th. The stock was acquired at an average cost of $2.52 per share, for a total transaction of $15,379,413.84. Following the completion of the transaction, the insider now directly owns 6,838,237 shares in the company, valued at $17,232,357.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 26.60% of the stock is owned by insiders.
Shares of Cesca Therapeutics (NASDAQ:KOOL) traded up 2.94% on Monday, hitting $3.15. The stock had a trading volume of 16,865 shares. The firm’s 50-day moving average price is $2.96 and its 200 day moving average price is $3.23. Cesca Therapeutics has a 12 month low of $1.85 and a 12 month high of $7.39. The firm’s market cap is $31.14 million.
Your IP Address:
About Cesca Therapeutics
Cesca Therapeutics Inc is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/cesca-therapeutics-inc-kool-receives-consensus-recommendation-of-from-brokerages/1708827.html
Receive News & Ratings for Cesca Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.